Log in

NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News

$9.18
-0.06 (-0.65 %)
(As of 07/31/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.80
Now: $9.18
$9.29
50-Day Range
$8.64
MA: $9.15
$9.54
52-Week Range
$8.05
Now: $9.18
$18.23
Volume23,965 shs
Average Volume32,228 shs
Market Capitalization$39.11 million
P/E Ratio4.41
Dividend YieldN/A
Beta0.76
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Read More
Opiant Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.16 out of 5 stars


Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.52 million
Cash Flow$0.28 per share
Book Value$8.41 per share

Profitability

Net Income$11.59 million

Miscellaneous

Employees16
Market Cap$39.11 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableNot Optionable
$9.18
-0.06 (-0.65 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

How has Opiant Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPNT stock has decreased by 15.4% and is now trading at $9.18.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Opiant Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opiant Pharmaceuticals
.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Opiant Pharmaceuticals
.

How can I listen to Opiant Pharmaceuticals' earnings call?

Opiant Pharmaceuticals will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings results on Tuesday, May, 12th. The technology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.21. The technology company earned $4.28 million during the quarter, compared to the consensus estimate of $4.63 million. Opiant Pharmaceuticals had a return on equity of 3.27% and a net margin of 29.58%.
View Opiant Pharmaceuticals' earnings history
.

What price target have analysts set for OPNT?

1 equities research analysts have issued 12-month price objectives for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next year. This suggests a possible upside of 357.5% from the stock's current price.
View analysts' price targets for Opiant Pharmaceuticals
.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

News headlines about OPNT stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave news stories about the technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Opiant Pharmaceuticals
.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 9,500 shares, a drop of 14.4% from the June 30th total of 11,100 shares. Based on an average daily trading volume, of 71,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company's shares are sold short.
View Opiant Pharmaceuticals' Current Options Chain
.

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Cyberark Software (CYBR), AT&T (T), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD) and Agenus (AGEN).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the following people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $9.18.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $39.11 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is www.opiant.com.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.